ImmuPharma Plc (LON:IMM) Chairman Tim McCarthy talks with DirectorsTalk about the phase 3 trials of lupuzor being opened up to Mauritius. Tim explains why the site is being opened up,
Northland Capital partners view on Immupharma PLC: Mauritius has a high proportion of Lupus sufferers. The Mauritian Government’s strong interest in Lupuzor™ demonstrates how Lupus is an unmet medical
ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, is pleased DirectorsTalk with a provide a further update on the progress of its Phase III clinical trial of Lupuzor(TM),
We initiate coverage for ImmuPharma plc (LON:IMM) * Blockbuster potential: We expect Lupuzor could achieve multi-billion dollar annual sales as a potential treatment for Lupus. The drug has also recently shown promise
ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, has told DirectorsTalk that today and tomorrow, 8 & 9 June, it is hosting a number of presentations on Lupuzor(TM),
Panmure Gordon Analyst Dr Mike Mitchell this morning said about Immupharma PLC “This morning ImmuPharma has announced the commencement of dosing in the first European patients in the company’s pivotal
ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, has given DirectorsTalk a further update on the progress of its Phase III clinical trial of Lupuzor(TM), its lead programme
ImmuPharma PLC (LSE:IMM) the specialist drug discovery and development company, has told DirectorsTalk that on 30 May 2016 it received notification by Alto Invest and its subsidiaries confirming that it has
Northland Capital partners view on Immupharma PLC LON:IMM: Alto’s investment further corroborates our view that ImmuPharma represents a good investment opportunity. The group’s lead drug, a potential treatment for Lupus,
ImmuPharma PLC (LSE:IMM) the specialist drug discovery and development company, has told DirectorsTalk that on 24 May 2016 it received notification by Alto Invest and its subsidiaries (“Alto”) confirming its holding
© 2025 – DirectorsTalk. All rights reserved. Reproduction in whole or in part, in any form or medium without express written permission is prohibited.
